Home > Boards > US Listed > Medical - Drugs > AVEO Pharmaceuticals, Inc. (AVEO)

So when this comea out approved it can

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Gungadin1 Member Profile
 
Followed By 1
Posts 455
Boards Moderated 0
Alias Born 07/17/19
160x600 placeholder
AVEO Oncology Announces Appointment of Scarlett Spring to its Board of Directors Business Wire - 11/19/2019 7:00:00 AM
AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Business Wire - 11/18/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:16:33 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 7:15:55 AM
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire - 11/12/2019 7:00:00 AM
AVEO Oncology & Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination w... Business Wire - 11/7/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 7:02:44 AM
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma Business Wire - 11/4/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 9:12:29 AM
AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (... Business Wire - 9/30/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2019 7:24:47 AM
AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire - 9/26/2019 7:00:00 AM
AVEO Oncology & EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell... Business Wire - 9/23/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 5:23:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 4:11:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 9:44:00 AM
AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carc... Business Wire - 9/10/2019 6:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2019 5:26:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 7:06:22 AM
AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire - 8/8/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 6:16:14 AM
Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology Business Wire - 8/1/2019 6:00:00 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 6/14/2019 8:03:55 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:02:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:01:28 PM
Gungadin1   Monday, 09/30/19 08:28:14 PM
Re: ezyE post# 4916
Post # of 5110 
So when this comea out approved it can be combined with optivo. Or keytruda and by changing the chemistry may buy me more time till that wonder drug comes out. This class and scoence has given me a chance And does have much value.Its probably not going to be the best nut will have an important lace for myself and many future sufer


Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist